Cingulate Therapeutics
Clinical trials sponsored by Cingulate Therapeutics, explained in plain language.
-
New ADHD pill aims to control symptoms for 16 hours
Disease control CompletedThis phase 3 trial tests whether a new formulation of dexmethylphenidate (CTx-1301) can improve attention and reduce ADHD symptoms in adults for up to 16 hours. Participants take an optimized dose (25, 37.5, or 50 mg) and complete math tests in a simulated classroom. The study co…
Phase: PHASE3 • Sponsor: Cingulate Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New ADHD drug shows promise for kids in Late-Stage trial
Symptom relief CompletedThis study tested a new medication called CTx-1301 (dexmethylphenidate) for children and teens aged 6 to 17 with ADHD. The goal was to see if it reduces ADHD symptoms better than a placebo. 103 participants took either the drug or a placebo, and researchers measured changes in AD…
Phase: PHASE3 • Sponsor: Cingulate Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC